Doctormag
  • Home
  • Categories
    • Aesthetics Surgery
    • Antonio Giordano
    • Dentist
    • Dermatology and Aesthetics
    • General Medicine
    • Healthcare Professions
    • Hygiene And Safety
    • Pharmaceutic Sector
    • Specialized Medicine
    • Unconventional Medicine
    • Wellness and Dieting
    • Works and Research
  • Pages
    • Handbook
    • Institutional Links
    • Medical Blogs
    • Privacy
    • Project
  • Rubrics
  • News
  • Video
  • Events
  • Join
Home » Antonio Giordano » Old drug could fight brain cancer by starving it to death

Old drug could fight brain cancer by starving it to death

May 18, 2016 by admin

Philadelphia, May 17th, 2016

Glioblastoma, the most common form of brain cancer is a deadly disease for which at present there is no cure. Now, researchers have published research results that show how repurposing the old drug flavopiridol could be an effective strategy to cut short sugar availability and impair cancer growth.
One of the most remarkable feature of glioblastoma cells is their ability to reprogram their metabolism switching towards a glycolytic energetic metabolism, which relies on high glucose uptake and consumption to sustain the cancer cell’s malignant activities. However, because flavopiridol, a synthetic flavonoid already used in the past against cancer, inactivates the enzyme glycogen phosphorylase, this metabolic switching could be used as a therapeutic target. The authors set out to test whether flavopiridol could be used to restrain glioblastoma cell growth by decreasing the availability of glucose as substrate for the glycolytic process, cutting off the tumor’s energy supply.
The results, published on the Journal of Cellular Physiology, comes from the Sbarro Health Research Organization (SHRO), at the Center for Biotechnology, Temple University and  the University of L’Aquila and Siena in Italy.
The ability of Flavopiridol to reduce glycolisys in glioblastoma cells and inhibit their proliferation is a significant step toward deriving new treatments for what is currently an incurable form of cancer. According to Annamaria Cimini of the University of L’Aquila, lead author of the study, “This points toward a possible new use of this compound or flavopiridol-derived formulations in combination with anti-proliferative agents in glioblastoma patients.”
“The design of new flavopiridol-based formulations, aimed at starving cancer cells cutting short the sugar they’re addicted to, may open up new therapeutic avenues for patients with glioblastoma,” says Antonio Giordano, founder and director of the Sbarro Institute for Cancer Research and Molecular Medicine and  Center for Biotechnology at Temple University in Philadelphia, PA USA  in collaboration with the Department of Medicine, Surgery & Neuroscience at the University of Siena, and University of L’ Aquila Italy.

 

http://www.ncbi.nlm.nih.gov/pubmed/27171480

 

 

Schermata 2014-03-19 alle 11.44.33

Related Posts

Tags

Share This

Facebook

Events

There are no events to display

February 2019
M T W T F S S
« Oct    
 123
45678910
11121314151617
18192021222324
25262728  

Tags

3d adipose tissue AIDS Alessandro Franco animation body cancer carcinoma Carmine Martino cellulite chemotherapy diabetes diet disease Doctor Doctormag emergency Epidermis health heart Heart Rate Variability HIV Human Health Foundation Onlus hyperglycemia hypertension liposuction liquid nitrogen medical medical video medicine muscles nutrition Obesity osteoporosis Pier Antonio Bacci pregnancy prof Antonio Giordano research Sbarro Health Research Organization skin surgery therapy turitv tv women

NETWORK

  • Ble Group

PARTNERS

  • Gruppo Mag
  • Sbarro Health Foundation
  • SCR Italy